Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 4/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764936 | 0.98 | TSHR (0.46) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL28930080 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL19135584 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL28191745 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL10460696 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL25121223 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL14515882 | 0.98 | LMNA (0.50) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL31065657 | 0.95 | LMNA (0.48) | TSHRLMNAOPRM1ALDH1A1TDP1 | |
| SCHEMBL30818337 | 0.93 | LMNA (0.46) | TSHRLMNAOPRM1DNM1FDPS | |
| Boric Acid SCHEMBL27917316 | 0.91 | LMNA (0.45) | TSHRLMNAOPRM1ALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376659-A1 | DERIVATION OF SOMATOTROPHS FROM STEM CELLS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-12-11 | — | — | US | claimed |
| EP-4519419-A1 | METHODS | Joincells Nordic AB (SE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213901-A1 | METHODS | JOINCELLS NORDIC AB (SE) | 2023-11-09 | — | — | WO | claimed |
| US-20210346394-A1 | Remyelination Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-11 | — | — | US | claimed |
| EP-3834842-A1 | ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | MERCK SHARP & DOHME CORP. (US) | 2021-06-16 | — | — | EP | claimed |
| US-20200332253-A1 | DERIVATION OF SOMATOTROPHS FROM STEM CELLS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-10-22 | — | — | US | claimed |
| EP-3707249-A1 | DERIVATION OF SOMATOTROPHS FROM STEM CELLS AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2020-09-16 | — | — | EP | claimed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | claimed |
| CN-111566206-A | Derivation of somatotropin cells from stem cells and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2020-08-21 | — | — | CN | claimed |
| EP-3496725-A1 | REMYELINATION THERAPIES | The Regents of The University of California (US) | 2019-06-19 | — | — | EP | claimed |
| US-20120282222-A9 | Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-11-08 | — | — | US | claimed |
| US-20110256096-A1 | Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-10-20 | — | — | US | claimed |
| WO-2011057064-A1 | IGF1R INHIBITOR BASED TREATMENT OF PROSTATE CANCER | LONG BRIAN (US) | 2011-05-12 | — | — | WO | claimed |
| US-20100152144-A1 | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease | HERMSMEYER R KENT | 2010-06-17 | — | — | US | claimed |
| US-7674783-B2 | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease | DIMERA INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-20100035855-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-11 | — | — | US | claimed |
| WO-2009020521-A2 | IDENTIFICATION AND TREATMENT OF ESTROGEN RESPONSIVE PROSTATE TUMORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20090036415-A1 | Identification and treatment of estrogen responsive prostate tumors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-02-05 | — | — | US | claimed |
| WO-2004047726-A2 | ESTROGEN BETA RECEPTOR AGONISTS TO PREVENT OR REDUCE THE SEVERITY OF CARDIOVASCULAR DISEASE | DIMERA INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-20040102427-A1 | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease | DIMERA, INCORPORATED | 2004-05-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | TSHR 284/4885LMNA 3275/4885OPRM1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.